Silk fibroin nanoparticles as a versatile oral delivery system for drugs of different biopharmaceutics classification system (BCS) classes: A comprehensive comparison
Source abstract
Abstract
Herein, silk fibroin nanoparticles (FNPs) were explored as a potential oral delivery system, with 04 representative oral drugs belonged to different Biopharmaceutics Classification System (BCS) classes, including ascorbic acid (class I), dextromethorphan (class II), paracetamol (class III), and paclitaxel (class IV). The 04 drug-loaded FNP formulas demonstrated spherical nanosized particles of 300–420 nm with dominant silk-II structures, negative zeta potentials of − 17 mV, varied entrapment efficiencies, and physico-chemical stabilities of > 3 months. In the gastrointestinal condition, the particles significantly enhanced the class-II- and class-IV-drug solubility and sustained their release rates to > 72 h. For the BCS class-I- and class-III-drugs, the particles prolonged the drug release to 6 h. Moreover, the FNP could bypass the pH variations in the gastrointestinal tract and increase the drug permeability across the intestinal membrane by facilitating the drug cellular internalizations. Conclusively, the FNP is a versatile system for the oral delivery of different pharmaceutical agents.Graphical abstract
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Silk-based biomaterials and applications · Biochemical and Structural Characterization · Phytochemical compounds biological activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. D.T. Pham, W. Tiyaboonchai, Fibroin nanoparticles: a promising drug delivery system. Drug Deliv. 27(1), 431–448 (2020). https://doi.org/10.1080/10717544.2020.173620810.1080/10717544.2020.1736208 ↗
2. D.T. Pham, N. Saelim, W. Tiyaboonchai, Crosslinked fibroin nanoparticles using EDC or PEI for drug delivery: physicochemical properties, crystallinity and structure. J. Mater. Sci. 53(20), 14087–14103 (2018). https://doi.org/10.1007/s10853-018-2635-310.1007/s10853-018-2635-3 ↗
3. V. Pandey, T. Haider, P. Jain, P.N. Gupta, V. Soni, Silk as a leading-edge biological macromolecule for improved drug delivery. J. Deliv. Sci. Technol. 55, 101294 (2020). https://doi.org/10.1016/J.JDDST.2019.10129410.1016/J.JDDST.2019.101294 ↗
4. D.T. Pham, N.T.P. Thao, B.T.P. Thuy, V.D. Tran, T.Q.C. Nguyen, N.N.T. Nguyen, Silk fibroin hydrogel containing Sesbania sesban L. extract for rheumatoid arthritis treatment. Drug Deliv. 29(1), 882–888 (2022). https://doi.org/10.1080/10717544.2022.205084810.1080/10717544.2022.2050848 ↗
5. D.T. Pham, P. Phewchan, K. Navesit, A. Chokamonsirikun, T. Khemwong, W. Tiyaboonchai, Development of metronidazole-loaded in situ thermosensitive hydrogel for periodontitis treatment. Turk. J. Pharm. Sci. 18(4), 510 (2021). https://doi.org/10.4274/TJPS.GALENOS.2020.0962310.4274/TJPS.GALENOS.2020.09623 ↗
6. S. Kapoor, S.C. Kundu, Silk protein-based hydrogels: promising advanced materials for biomedical applications. Acta Biomater. 31, 17–32 (2016). https://doi.org/10.1016/J.ACTBIO.2015.11.03410.1016/J.ACTBIO.2015.11.034 ↗
7. H. Zheng, B. Zuo, Functional silk fibroin hydrogels: preparation, properties and applications. J. Mater. Chem. B 9(5), 1238–1258 (2021). https://doi.org/10.1039/D0TB02099K10.1039/D0TB02099K ↗
8. Y.Y. Jo, H. Kweon, D.W. Kim, M.K. Kim, S.G. Kim, J.Y. Kim et al., Accelerated biodegradation of silk sutures through matrix metalloproteinase activation by incorporating 4-hexylresorcinol. Sci. Rep. 7(1), 1–11 (2017). https://doi.org/10.1038/srep4244110.1038/srep42441 ↗
9. S.H. Tran, C.G. Wilson, F.P. Seib, A review of the emerging role of silk for the treatment of the eye. Pharm. Res. 35(12), 1–16 (2018). https://doi.org/10.1007/S11095-018-2534-Y/FIGURES/310.1007/S11095-018-2534-Y/FIGURES/3 ↗
10. R. Jeencham, M. Sutheerawattananonda, S. Rungchang, W. Tiyaboonchai, Novel daily disposable therapeutic contact lenses based on chitosan and regenerated silk fibroin for the ophthalmic delivery of diclofenac sodium. Drug Deliv. 27(1), 782–790 (2020). https://doi.org/10.1080/10717544.2020.176543210.1080/10717544.2020.1765432 ↗
11. R. Jeencham, M. Sutheerawattananonda, W. Tiyaboonchai, Preparation and characterization of chitosan/regenerated silk fibroin (CS/RSF) films as a biomaterial for contact lenses-based ophthalmic drug delivery system. Int. J. Appl. Pharm (2019). https://doi.org/10.22159/ijap.2019v11i4.3328310.22159/ijap.2019v11i4.33283 ↗
12. K. Cao, Y. Liu, S. Ramakrishna, Recent developments in regenerated silk fiber. J. Nanosci. Nanotechnol. 17(12), 8667–8682 (2017). https://doi.org/10.1166/JNN.2017.1501010.1166/JNN.2017.15010 ↗
13. S.H. Kim, Y.S. Nam, T.S. Lee, W.H. Park, Silk fibroin nanofiber, electrospinning, properties, and structure. Polym. J. 35(2), 185–190 (2003). https://doi.org/10.1295/polymj.35.18510.1295/polymj.35.185 ↗
14. T.P. Nguyen, Q.V. Nguyen, V.H. Nguyen, T.H. Le, V.Q.N. Huynh, D.V.N. Vo et al., Silk fibroin-based biomaterials for biomedical applications: a review. Polymers (2019). https://doi.org/10.3390/POLYM1112193310.3390/POLYM11121933 ↗
15. T.K. Mwangi, R.D. Bowles, D.M. Tainter, R.D. Bell, D.L. Kaplan, L.A. Setton, Synthesis and characterization of silk fibroin microparticles for intra-articular drug delivery. Int. J. Pharm. 485, 7 (2015). https://doi.org/10.1016/J.IJPHARM.2015.02.05910.1016/J.IJPHARM.2015.02.059 ↗
16. A. Nisal, R. Sayyad, P. Dhavale, B. Khude, R. Deshpande, V. Mapare et al., Silk fibroin micro-particle scaffolds with superior compression modulus and slow bioresorption for effective bone regeneration. Sci. Rep. 8(1), 1–10 (2018). https://doi.org/10.1038/s41598-018-25643-x10.1038/s41598-018-25643-x ↗
17. E. Wenk, A.J. Wandrey, H.P. Merkle, L. Meinel, Silk fibroin spheres as a platform for controlled drug delivery. J. Control. Release 132(1), 26–34 (2008). https://doi.org/10.1016/J.JCONREL.2008.08.00510.1016/J.JCONREL.2008.08.005 ↗
18. A. Zuluaga-Vélez, A. Quintero-Martinez, L.M. Orozco, J.C. Sepúlveda-Arias, Silk fibroin nanocomposites as tissue engineering scaffolds—a systematic review. Biomed. Pharmacother. (2021). https://doi.org/10.1016/J.BIOPHA.2021.11192410.1016/J.BIOPHA.2021.111924 ↗
19. W. Sun, D.A. Gregory, M.A. Tomeh, X. Zhao, Silk fibroin as a functional biomaterial for tissue engineering. Int. J. Mol. Sci. 22(3), 1–28 (2021). https://doi.org/10.3390/IJMS2203149910.3390/IJMS22031499 ↗
20. M. Vidya, S. Rajagopal, Silk fibroin: a promising tool for wound healing and skin regeneration. Int. J. Polym. Sci. (2021). https://doi.org/10.1155/2021/906992410.1155/2021/9069924 ↗
21. M.T. Sultan, O.J. Lee, S.H. Kim, H.W. Ju, C.H. Park, Silk fibroin in wound healing process. Adv. Exp. Med. Biol. 1077, 115–126 (2018). https://doi.org/10.1007/978-981-13-0947-2_710.1007/978-981-13-0947-2_7 ↗
22. V. Pandey, T. Haider, A.R. Chandak, A. Chakraborty, S. Banerjee, V. Soni, Surface modified silk fibroin nanoparticles for improved delivery of doxorubicin: development, characterization, in-vitro studies. Int. J. Biol. Macromol. 164, 2018–2027 (2020). https://doi.org/10.1016/J.IJBIOMAC.2020.07.32610.1016/J.IJBIOMAC.2020.07.326 ↗
23. D.T. Pham, N. Saelim, W. Tiyaboonchai, Design of experiments model for the optimization of silk fibroin based nanoparticles. Int. J. Appl. Pharm. 10(5), 195–201 (2018). https://doi.org/10.22159/ijap.2018v10i5.2813910.22159/ijap.2018v10i5.28139 ↗
24. P. Chomchalao, P. Nimtrakul, D.T. Pham, W. Tiyaboonchai, Development of amphotericin B-loaded fibroin nanoparticles: a novel approach for topical ocular application. J. Mater. Sci. 55(12), 5268–5279 (2020). https://doi.org/10.1007/s10853-020-04350-x10.1007/s10853-020-04350-x ↗
25. D.T. Pham, N. Saelim, W. Tiyaboonchai, Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment. Drug Deliv. Transl. Res. (2019). https://doi.org/10.1007/s13346-019-00682-710.1007/s13346-019-00682-7 ↗
26. D.T. Pham, N. Saelim, R. Cornu, A. Béduneau, W. Tiyaboonchai, Crosslinked fibroin nanoparticles: investigations on biostability, cytotoxicity, and cellular internalization. Pharmaceuticals (Basel, Switzerland) 13(5), 86 (2020). https://doi.org/10.3390/ph1305008610.3390/ph13050086 ↗
27. D.T. Pham, N. Saelim, W. Tiyaboonchai, Alpha mangostin loaded crosslinked silk fibroin-based nanoparticles for cancer chemotherapy. Colloids Surf. B 181, 705–713 (2019). https://doi.org/10.1016/j.colsurfb.2019.06.01110.1016/j.colsurfb.2019.06.011 ↗
28. D.T. Pham, W. Tiyaboonchai, Fibroin-coated poly(ethylenimine)-docusate nanoparticles as a novel drug delivery system. Curr. Sci. 121(6), 775–780 (2021)10.18520/cs/v121/i6/775-780 ↗
29. Y. Cao, B. Wang, Biodegradation of silk biomaterials. Int. J. Mol. Sci. 10(4), 1514–1524 (2009). https://doi.org/10.3390/ijms1004151410.3390/ijms10041514 ↗
30. S. Gou, Y. Huang, Y. Wan, Y. Ma, X. Zhou, X. Tong et al., Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis. Biomaterials 212, 39–54 (2019). https://doi.org/10.1016/j.biomaterials.2019.05.01210.1016/j.biomaterials.2019.05.012 ↗
31. D.T. Pham, C. Tetyczka, S. Hartl, M. Absenger-Novak, E. Fröhlich, W. Tiyaboonchai, E. Roblegg, Comprehensive investigations of fibroin and poly(ethylenimine) functionalized fibroin nanoparticles for ulcerative colitis treatment. J. Drug Deliv. Sci. Technol. (2019). https://doi.org/10.1016/j.jddst.2019.10148410.1016/j.jddst.2019.101484 ↗
32. J. Wu, J. Wang, J. Zhang, Z. Zheng, D.L. Kaplan, G. Li, X. Wang, Oral delivery of curcumin using silk nano- and microparticles. ACS Biomater. Sci. Eng. 4(11), 3885–3894 (2018). https://doi.org/10.1021/acsbiomaterials.8b0045410.1021/acsbiomaterials.8b00454 ↗
33. K. Roy, Y.S. Patel, R.K. Kanwar, R. Rajkhowa, X. Wang, J.R. Kanwar, Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells. Int. J. Nanomed. 11, 25–44 (2015). https://doi.org/10.2147/IJN.S9181010.2147/IJN.S91810 ↗
34. Y. Ma, L. Duan, J. Sun, S. Gou, F. Chen, Y. Liang et al., Oral nanotherapeutics based on Antheraea pernyi silk fibroin for synergistic treatment of ulcerative colitis. Biomaterials 282, 121410 (2022). https://doi.org/10.1016/J.BIOMATERIALS.2022.12141010.1016/J.BIOMATERIALS.2022.121410 ↗
35. G.L. Amidon, H. Lennernäs, V.P. Shah, J.R. Crison, A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3), 413–420 (1995). https://doi.org/10.1023/A:101621280428810.1023/A:1016212804288 ↗
36. N.N.T. Nguyen, D.T. Pham, D.T. Nguyen, T.T.L. Trinh, Bilayer tablets with sustained-release metformin and immediate-release sitagliptin: preparation and in vitro/in vivo evaluation. J. Pharm. Investig. 51(5), 579–586 (2021). https://doi.org/10.1007/S40005-021-00533-Z10.1007/S40005-021-00533-Z ↗
37. P. Shi, S.A. Abbah, K. Saran, Y. Zhang, J. Li, H.-K. Wong, J.C.H. Goh, Silk fibroin-based complex particles with bioactive encrustation for bone morphogenetic protein 2 delivery. Biomacromol 14(12), 4465–4474 (2013). https://doi.org/10.1021/bm401381s10.1021/bm401381s ↗
38. F. Mottaghitalab, M. Farokhi, M.A. Shokrgozar, F. Atyabi, H. Hosseinkhani, Silk fibroin nanoparticle as a novel drug delivery system. J. Control. Release 206, 161–176 (2015). https://doi.org/10.1016/j.jconrel.2015.03.02010.1016/j.jconrel.2015.03.020 ↗
39. H.Y. Wang, Y.Q. Zhang, Processing and characterisation of a novel electropolymerized silk fibroin hydrogel membrane. Sci. Rep. 4(1), 1–11 (2014). https://doi.org/10.1038/srep0618210.1038/srep06182 ↗
40. S. Kumar, N. Dilbaghi, R. Saharan, G. Bhanjana, Nanotechnology as emerging tool for enhancing solubility of poorly water-soluble drugs. BioNanoScience 2(4), 227–250 (2012). https://doi.org/10.1007/S12668-012-0060-710.1007/S12668-012-0060-7 ↗
41. ISO - ISO 10993–5:2009 - Biological evaluation of medical devices—Part 5: Tests for in vitro cytotoxicity. (n.d.). https://www.iso.org/standard/36406.html. Accessed 17 May 2022
42. J.E. Liebmann, J.A. Cook, C. Lipschultz, D. Teague, J. Fisher, J.B. Mitchell, Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br. J. Cancer 68(6), 1104–1109 (1993). https://doi.org/10.1038/BJC.1993.48810.1038/BJC.1993.488 ↗
43. L.J. Bray, S. Suzuki, D.G. Harkin, T.V. Chirila, Incorporation of exogenous RGD peptide and inter-species blending as strategies for enhancing human corneal limbal epithelial cell growth on Bombyx mori silk fibroin membranes. J. Funct. Biomater. 4(2), 74–88 (2013). https://doi.org/10.3390/JFB402007410.3390/JFB4020074 ↗
44. B. Srinivasan, A.R. Kolli, M.B. Esch, H.E. Abaci, M.L. Shuler, J.J. Hickman, TEER measurement techniques for in vitro barrier model systems. J. Lab. Autom. 20(2), 107 (2015). https://doi.org/10.1177/221106821456102510.1177/2211068214561025 ↗